In patients with single ventricle physiology, Fontan circulation is considered as the optimal surgical approach, although it entails a growing incidence of late complications. It has been speculated that the association of bidirectional cavopulmonary shunt (BCPS) and additional pulmonary blood flow (APBF) might provide long-lasting palliation. The present study was undertaken to assess the long-term outcome of this strategy.
INTRODUCTION
Patients born with single ventricle physiology have a poor natural prognosis. Introduced in the early 1970s, the Fontan procedure and its modifications have changed this unsatisfactory outcome. However, the Fontan circulation carries in itself the substrates for late dysfunction of the pulmonary arterial and systemic venous circulations [1] . The very late results of Fontan circulation may be disappointing [2] . On the other hand, it is well established that patients who are fortunate enough to have a good balance between the systemic and pulmonary blood flows (spontaneously or after palliative surgery) may have a long-lasting satisfactory outcome [3] . From a theoretical point of view, a bidirectional cavopulmonary shunt (BCPS) associated with a well-calibrated source of additional pulmonary blood flow (APBF) should yield such a favourable haemodynamic status. We proposed, in the late 1980s, the hypothesis that BCPS with APBF may provide a long-lasting, and potentially, definitive palliation. The early results of this approach have been reported [4] , but the late outcome remains to be determined.
MATERIALS AND METHODS

Study design
Since the early 1990s, most patients with single ventricle physiology have been palliated by the association of a BCPS and one (or several) additional sources of pulmonary blood flow. The present study was undertaken to evaluate the late results of this approach in a well-selected group of patients. Permission to perform a health records review was obtained from the Paris V University Ethics Committee. The need for individual consent was waived.
Study population
A group of 70 patients was selected, including all the patients who met three inclusion criteria: (i) uniform medical management; all patients were considered, at the time of BCPS as good candidates for Fontan circulation; nevertheless, they were managed by the same attending team (D.S. as cardiologist and P. R.V. as surgeon) with the intention of avoiding Fontan completion as much as possible, (ii) palliation by BCPS with APBF between 1990 and 2000 and (iii) living in France.
The anatomic characteristics of the patients are reported in Table 1 . Forty-one patients (59%) were male. Most patients (77%) had one palliative procedure or more before BCPS; these procedures are reported in Table 2 .
Surgical management
Median age at BCPS was 2 years (range: 0.1-27 years); 35 patients (50%) were <2 years, 14 (20%) were between 2 and 5 years of age and 21 (30%) were 5 years or older. Unilateral BCPS was performed in 60 patients (right in 58, left in 2). Nine children had bilateral BCPS and one patient [with interrupted inferior vena cava (IVC)] had a Kawashima procedure.
APBF was antegrade through the native pulmonary outflow tract (stenosed or banded) in 43 patients (61%) or retrograde via aortopulmonary shunts in 27 (39%). Associated procedures (listed in Table 3 ) were performed in 35 patients (50%).
Follow-up and data analysis
Follow-up data were obtained during a 3-month closing interval (April 2011 to June 2011). Information was obtained for 67 patients (96% complete).
Primary end-points included survival, need for heart transplantation (HTx), need for Fontan completion and suitability for Fontan completion. Functional outcome, including evolution of ventricular function, was evaluated as well.
Continuous data were tested for normality using the Kolmogorov-Smirnov test. Data were described as frequencies, medians with ranges and means with standard deviations, as appropriate. Comparisons were performed using the χ 2 or Fisher's exact tests for categorical variables, and the Mann-Whitney U-test for continuous variables. Estimates of time-related survival and freedom from adverse events were calculated using the Kaplan-Meier method. All analyses were performed using SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). The relationship between age at BCPS and the probability of clinical failure (death, HTx or unsuitability for Fontan completion) was evaluated using a Loess smoother ( performed with the 'Design' software in the R statistical package-www.r-project.org). This is a non-parametric regression estimate of the relationship between the two variables, using locally weighted polynomial regression. It allows estimation of the curve of the probability of bad outcome during follow-up as a function of age at BCPS. Patients lost to follow-up were not included in the analysis. Figure 1 provides an overview of the patient population. Overall, 7 patients (10%) died (two early, three late and two after HTx), 3 patients (4.2%) were lost to follow-up, 2 patients (2.8%) with BCPS and APBF were unsuitable for Fontan completion and 58 patients (83%) were alive and well (50 after Fontan completion, 4 after HTx, 4 with BCPS and APBF).
RESULTS
Early results
Two patients (2.8%) died early after BCPS with APBF. A 1-month old infant died of severe cyanosis because of acute thrombosis of the cavopulmonary anastomosis. The other death (in a 6-month old child) was due to mediastinitis. Median duration of mechanical ventilation was 12 h (range: 4-288 h) and median intensive care unit length of stay was 3 days (range: 1-30 days). Postoperative complications occurred in 17 patients (24%) and included: superior vena cava (SVC) syndrome (5), chylothorax (4), prolonged pleural effusions (2) and miscellaneous (6).
Late results
Three patients were lost to follow-up. Mean follow-up of the 65 remaining patients was 13.5 ± 4 years (range: 1-20 years). Mean age of the patients at last follow-up was 18 ± 6 years.
Late mortality. Five patients died during follow-up. Median age at death was 19 years (range: 2-28 years) and median time between BCPS and death was 4 years (range: 1-13 years). Two patients died early after HTx and three patients died from ventricular failure while on the transplant waiting list. The actuarial survival rate for the overall population was 89 ± 4% at 15 years (Fig. 2) .
Incremental risk factors for late mortality were: age at BCPS with APBF (P = 0.05) (median age at BCPS for the five patients who died was 12 years-range: 0.3-27 years), low shortening fraction of the single ventricle (P = 0.007) and postoperative complications after BCPS (P = 0.002). 
CONGENITAL
Heart transplantation. Five patients underwent HTx after BCPS with two early deaths and no late mortality. Median age at transplantation was 19 years (range: 2-28 years) and median time between BCPS and transplantation was 5 years (range: 2-13 years). Incremental risk factors for HTx were age at BCPS (P = 0.07) and postoperative complications after BCPS (P = 0.002).
An additional patient underwent successful transplantation for ventricular failure after Fontan completion.
Fontan completion. Fifty-one patients underwent Fontan completion because of worsening cyanosis and/or decreasing exercise capacity. Median age at Fontan completion was 9 years (range: 2-23 years) and median time between BCPS and Fontan completion was 7 years (range: 1-16 years).
In 40 patients, Fontan completion was performed as the first subsequent step after BCPS with APBF. In the 11 other patients, additional interventions were performed during the interim period between BCPS and Fontan completion and included: additional aortopulmonary shunt (5), aortopulmonary shunt with enlargement of the bulboventricular foramen (1), surgical pulmonary artery angioplasty (1), percutaneous pulmonary angioplasty (2), common atrioventricular (AV) valve repair (1) and mitral valve replacement (1).
Fontan completion was carried out using an extracardiac conduit in 47 patients (92%) and an intracardiac lateral tunnel in 4. Fenestration was performed in 46 cases (90%). Associated procedures were required in four patients ( pulmonary angioplasty in three, AV valve replacement in one).
There was no early or late mortality following Fontan completion. One patient underwent successful HTx 2.5 years after Fontan completion because of severe AV valve regurgitation and ventricular failure. Median follow-up after Fontan completion for the remaining 50 patients was 7 years (range: 0.4-19 years). At last follow-up, 46 patients (92%) were in NYHA functional class I/ II; median oxygen saturation at rest was 95% (range: 84-99%); dysfunction of the single ventricle (shortening fraction <25%) was noted in 6 patients (12%) and more than trivial regurgitation of the AV valve in 7 (14%).
Deterioration of ventricular function occurred in seven patients following Fontan completion (one had HTx). Incremental risk factors for ventricular dysfunction after Fontan completion were older age at BCPS (P = 0.02) and the presence of antegrade pulmonary blood flow in addition to BCPS (P = 0.03).
Patients surviving with BCPS and APBF. At last follow-up, six patients (9%) were surviving with BCPS and APBF with a median age of 20 years (range: 13-33 years).
Among these six patients, four had a satisfactory clinical palliation (in two of them, an additional aortopulmonary shunt had been performed during the interim period). These patients were considered as adequate candidates for Fontan completion if indicated.
The last two patients were deemed unsuitable for Fontan completion despite progressive clinical deterioration, because of stable ventricular dysfunction with AV valve regurgitation in one, and pulmonary artery hypoplasia and increased pulmonary pressure in the second. These two patients, 33 and 19 years old, were in functional class II, with a mean oxygen saturation at rest of 85%. One was leading an active, although limited, professional life; the other had severe psychiatric disorders.
Considering mortality (early and late), HTx and unsuitability for Fontan completion as clinical failures, 13 patients (19%) failed. Incremental risk factors for clinical failure included age at BCPS (P = 0.01) and postoperative complications after BCPS (P = 0.001). The relationship between age at BCPS and the probability of clinical failure is illustrated in Fig. 3 .
Considering late mortality, HTx and Fontan completion as strategic failures of the surgical approach, the actuarial freedom from these events was 71 ± 6% at 5 years and 20 ± 5% at 10 years (Fig. 4) .
DISCUSSION
In patients with single ventricle physiology, the surgical protocol adopted in most centres follows a staging approach and includes BCPS and later Fontan completion. Even if widely accepted, this protocol is still a matter for discussion and many points remain controversial.
BCPS has beneficial effects on both the systemic arterial oxygen saturation (by increasing effective pulmonary blood flow) and the ventricular function (by volume unloading the ventricle) [5] . It is commonly advocated to perform BCPS early in life, in order to provide optimal preservation of ventricular function [6] .
The potential usefulness or harmfulness of leaving, in association with BCPS, other sources of APBF has been the subject of many discussions. Controversial data have been reported regarding mortality and morbidity, ventricular loading and function, systemic venous pressure and SVC syndrome, pulmonary artery pressure, growth of the pulmonary arteries, development of pulmonary arteriovenous malformations or systemic venous collaterals and suitability for Fontan completion [7] [8] [9] [10] [11] . From this information, and even if it is sometimes contradictory, it can be assumed that BCPS with an 'appropriate' APBF provides adequate oxygen saturation and does not impair ventricular or AV valve functions. BCPS with APBF may yield long-lasting adequate palliation and may even be considered as a potential definitive palliation, particularly in high-risk Fontan patients Figure 3 : Assessment of the relationship between age at BCPS with APBF and probability of clinical failure (death, HTx, unsuitability for Fontan) using a loess smoother estimate. Tick marks show the distribution of all patients. [12, 13] . On a theoretical background, it is possible to reach a satisfactory level of arterial oxygen without excessive loading of the ventricle, by adding to the BCPS an 'appropriate' amount of pulmonary blood flow [14] . Although difficult to define, an 'appropriate' APBF is probably reached when the pulmonary to systemic blood flow ratio is close to 1. Excessive pulmonary blood flow, which may overload the ventricle and damage the pulmonary vascular bed, must be avoided. One of the main practical difficulties of this approach is to maintain an 'appropriate' level of APBF as the child grows.
The Fontan procedure ( particularly its last modification using an extracardiac conduit) can be carried out with a low early risk and yields satisfactory mid-term results. However, there is growing evidence that the very late results of Fontan circulation may be disappointing. By definition, in a Fontan circulation, the pressure is equivalent in the systemic venous system and in the pulmonary arterial bed whereas, in a normal biventricular circulation, the mean systemic venous pressure is <10 mmHg and the mean pulmonary arterial pressure at least 15 mmHg to keep the pulmonary vasculature patent. Therefore, Fontan circulation imposes caval hypertension ( particularly in the IVC system), as well as relative pulmonary arterial hypotension (in addition to the absence of pulsatility) [1] . This so-called 'Fontan paradox' explains the modes of late failure of Fontan circulation: proteinlosing enteropathy, plastic bronchitis, hepatic and renal failure, progressive thrombo-embolic deterioration of the pulmonary vascular bed, chronic underloading of the systemic ventricle with chronic low output state [2] . For all these reasons, it may be reasonable to avoid Fontan circulation or, at least, to delay Fontan construction as much as possible.
With all these considerations in mind, we decided, in the early 1990s, to keep the single ventricle patients with BCPS and APBF as long as possible. This approach was assumed to provide adequate oxygen saturation without excessive ventricular volume loading, solve the Fontan paradox by maintaining a low pressure in the IVC system and improve pulmonary perfusion by providing some pulsatility. Fontan completion was not planned systematically, but performed only when clinical deterioration occurs. The present study reports the long-term results of this strategy.
As a strategy for definitive palliation, BCPS with APBF is a failure
Considering that BCPS with APBF failed as a strategy when the patient died, underwent HTx because of ventricular failure or underwent Fontan completion because of clinical deterioration, the probability of freedom from failure was 71% at 5 years and only 20% at 10 years. At last follow-up, only four patients (6%) were doing well with BCPS and APBF. Most patients had to undergo Fontan completion because of inadequate pulmonary blood flow. Increasing cyanosis may be due to several factors, including decreasing SVC to IVC blood flow ratio with age, development of pulmonary arteriovenous malformations or systemic venous collaterals, and surgical inability to maintain 'appropriate' APBF. In some patients, we tried to maintain a satisfactory status by adding a new or bigger aortopulmonary shunt. This nearly always failed with time. Therefore, when the clinical situation is deteriorating (worsening cyanosis, decreasing functional capacity), Fontan completion should be performed as a first option, if allowed by ventricular and pulmonary vascular status.
As a clinical approach, BCPS with APBF may be a successful option
Actuarial survival was 89% at 15 years after BCPS with APBF. This confirms the results noted in other series in which patients were systematically entered in a staging to Fontan policy [15] [16] [17] . In Tanoue's report, among 333 patients who had BCPS, actuarial survival was 90% at 10 years [15] . In the Melbourne experience which includes 212 patients with BCPS, survival was 89% at 15 years [16] . In these two series, the Fontan completion rate was 69 and 66%, respectively, whereas it was 73% in our experience. Although the information is scarce, these data suggest that adding some pulmonary blood flow to BCPS may not impair survival and the rate of suitability for Fontan [12, 13] .
Considering death, HTx and unsuitability for Fontan as clinical failures, there was a 19% failure rate. Nearly all failures were related to progressive deterioration in ventricular function, usually associated with AV valve regurgitation (only one patient could not undergo Fontan completion because of anatomic factors). The question then arises to know whether excessive pulmonary blood flow (due to APBF) with ventricular volume overloading may, in part, explain this incidence of ventricular dysfunction. There are some preliminary answers to this question. On one hand, ventricular failure may occur in single ventricle patients, whatever the surgical approach is [18] . This is one of the most frequent modes of late failure, even after the Fontan procedure in which optimal volume unloading is provided [2] . On the other hand, and even if the results should be taken with caution because of the small number of patients, older age at the time of BCPS with APBF was associated with an increased risk of adverse events (including postoperative complications, late mortality, need for transplantation and ventricular dysfunction after Fontan completion). These data strongly suggest that BCPS should be performed early in life in order to provide early volume unloading [6] . However, there is also some evidence to support that BCPS should not be achieved too early (before 3 months of age) [19] .
Median time between BCPS and Fontan completion was 7 years. Results following Fontan completion were satisfactory (no mortality and no major complication after a median follow-up of 7 years). This suggests that delaying Fontan completion as long as possible may not impair the results of this procedure. This conclusion is supported by other recent reports [20] . It is usually accepted that the Fontan circulation per se creates a situation with potential deleterious consequences. Delaying Fontan completion just mechanically delays the establishment of a potentially dangerous situation. However, there is no evidence to suggest that delaying Fontan completion may influence the incidence, delay of outset or severity of Fontan complications.
Study limitations
The retrospective nature of the study is a limitation. The study population was deliberately limited to a selected group of patients (i) living in France (to limit the number of patients who are lost to follow-up), (ii) operated upon before 2000 (to obtain a minimal follow-up of 10 years) and (iii) treated by the same attending medico-surgical team with the firm intention of delaying Fontan completion as far as possible, despite the fact that the patients were, at the time of BCPS, good candidates for a Fontan pathway. This resulted in the inclusion of 40% of patients having BCPS in our institution during the study period. The study group is therefore small and the adverse events rare; statistical results must be interpreted with caution and potential bias may have been introduced. Although this issue is out of the scope of the present study, the analysis of the results in the patients who were excluded, could provide valuable information.
CONCLUSIONS
BCPS with APBF provides a satisfactory palliation in the mid-term, but not in the long run; it cannot serve, except in very rare cases, as a definitive palliation. This approach does not impair the suitability for Fontan completion and the early and late results of the Fontan procedure. The clinical need for Fontan completion is delayed (by a median time of 7 years) and the potential deleterious consequences of Fontan circulation are therefore postponed. Early BCPS with its related ventricular volume unloading may improve the results regarding ventricular function.
APPENDIX. CONFERENCE DISCUSSION
Dr F. Hanley (Stanford, CA, USA): I have a couple of questions. This cohort of 70 patients that received the Glenn and the extra source of flow during that time period, was that all of your patients, or a selected group? Were there other patients who only got a bidirectional Glenn during that time period?
Dr Gerelli: This is a selected group by Professor Sidi and Professor Vouhé. Dr Hanley: So how were they selected would be the next question? Dr P. Vouhé (Paris, France): This is obviously one of the weaknesses of this study. This is a very selected group: 1) operated before 2000 to get a long follow-up, 2) operated upon by myself, and 3) living in France. This represents only 30 to 40% of the patients who underwent BCPS during this period.
Dr Hanley: So the next important question is why did you put an extra source in some patients and not in others, because that is very important if we try to generalize these conclusions, because we now have a very selected group of patients.
Dr Vouhé: This was actually in the hope of getting definitive palliation. This was a selected group of patients with good ventricular function who were supposed to become good candidates for a Fontan. The idea was to delay as much as possible the need for Fontan and, hopefully, to avoid Fontan completely. This, obviously, was not the case.
Dr Hanley: So if you were faced with a patient back in that decade and you were going in to do the Glenn, you decided to put an extra source of pulmonary blood flow in the most favourable subgroup, is that what you are saying?
Dr Vouhé: Yes. We still do it the same way. Dr Hanley: And in the other ones that were less favourable, you did an isolated Glenn with no extra source of pulmonary blood flow?
Dr Vouhé: Exactly. Dr Hanley: So that is interesting in and of itself. I guess my next question relates to if the goal here was to go as far as you could without a Fontan, it is inevitable that if you do a Glenn and a shunt, for example (which was a big subgroup) in a two-year-old, within a very short period of time, a year or two, three at the outside, that shunt is either going to be gone or completely insignificant. In the 51 Fontans, you did do additional shunting in 11 of the 51, but in 40 you did not. So what was your thinking there? If the goal was to prolong things as far as possible, why did you not do an extra shunt in the other 40 to prolong things even further?
Dr Vouhé: I think that the main decision-making point was ventricular function. Obviously, one of the problems with this approach is to avoid significant overloading of the ventricle. When ventricular function was very good, we tended to place another shunt. When ventricular function was borderline, the first option was to go immediately towards Fontan completion.
Dr Hanley: So that was the thinking behind it. There was specific thinking among those 51 patients whether or not to go with another shunt?
Dr Vouhé: Yes. Dr Hanley: So if the horse was running fast, you continued with another shunt. If things were slowing down, you went to the Fontan? Dr Vouhé: Yes. Dr Hanley: All right. I do not know if there are other questions. I mean, I have a couple of other thoughts having had the opportunity to read the manuscript. If there are other people, I will defer, but I do have a couple of other thoughts.
You also showed that in terms of late ventricular failure, one of the risk factors was antegrade extra source of pulmonary blood flow but not retrograde source of pulmonary blood flow. That is the exact opposite of what I would have thought because with a B-T shunt, you have got diastolic runoff, potentially coronary insufficiency, and I would think with equal size shunts, your ventricle would be better preserved with antegrade extra flow, not retrograde through a shunt. But your study found the exact opposite. What is your thought behind that?
Dr Vouhé: This is exactly the opposite of what was said by your paper from some years ago. As you could see from our paper, the statistical significance was very low. Maybe it is due to the small number of patients. I have no clear explanation for that.
Dr Hanley: I guess I have then, just one more comment. I think everybody agrees that Fontans are not perfect, and that once you do a Fontan, the clock does start ticking. But that is slightly over-simplistic because it is not as though everybody is great until you do the Fontan and then the clock starts ticking. There is another clock that is ticking before the Fontan, and it is a complex interplay of waiting long enough but not waiting too long before starting the Fontan in order to get the best long-term outcome.
I do not know that anybody has ever had a series where they have said let's just do cavopulmonary shunts with no extra source of flow and then let them go as long as possible. Who knows how long they could go before doing a Fontan. We all jump into the Fontan essentially as early as possible. I do not know that that is the right thing, but maybe we ought to do a study where we do not do an extra source and see how far we can go before doing the Fontan.
Dr Vouhé: You are perfectly right. The bad thing is to be born with a single ventricle.
Dr S. Qureshi (London, UK): Frank, before you sit down, can I ask -I know it is not your paper, but just to get the other side of it. Are there any patients in your practice where you do exactly what Pascal was doing, which is additional pulmonary blood flow?
Dr Hanley: Generally we do not. Our general approach is to try to unload the ventricle completely and not do an extra source of pulmonary blood flow, and usually that will mean even if there is antegrade flow, we will get rid of it for the most part. But there is the occasional Glenn patient where you do the Glenn, and you are too desaturated in the operating room, then we will leave an extra source only for a need for oxygenation. That is pretty much the way we would approach it.
Dr Qureshi: Yes, okay. Dr T. Ebels (Groningen, Netherlands): Our policy is to do the Fontan procedure when the patients become symptomatic, so as early as is possible. We have a series of 57 patients in which we left additional pulmonary blood flow together with the bidirectional Glenn, and the effect of that is essentially only that when we do the Fontan, we can fit in a larger prosthesis.
So if you accept that the size of the prosthesis is important for the Fontan, then that may be an advantage depending on how large the patient will become. Because as you well know, somebody that will remain small might not need as large a prosthesis as a giant. So I think it is all about the anticipated size of the patient.
So there is some advantage in the additional pulmonary blood flow, in that it might permit us to postpone the Fontan, rather, and fit a large prosthesis.
